Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv(TM) (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
THOUSAND OAKS, Calif., Jan. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of Parsabiv (etelcalcetide), an inves... Biopharmaceuticals Amgen, Parsabiv, etelcalcetide, hyperparathyroidism
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: American Medical Association (AMA) | Dialysis | Hemodialysis | Hormones | Hyperparathyroidism | Marketing | Pharmaceuticals | Study